Investors

Press Releases

Press releases issued by Palatin are accessible below. These press releases contain additional information about our business, clinical trial developments, research and development activities, financial achievements, and strategic partnerships.

Select Year
Search …

Found 287 Results

Palatin to Present at the H.C. Wainwright 25th Annual Global Investment Conference

September 7, 2023

Palatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease

September 7, 2023

Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment

August 10, 2023

Palatin’s Vyleesi® Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study

August 8, 2023

Palatin Announces Direct-to-Consumer Telehealth Partnership with UpScriptHealth™ for Vyleesi®

August 7, 2023

Palatin to Participate in Canaccord Genuity’s 43rd Annual Growth Conference

August 4, 2023

Palatin Announces Preliminary Fourth Quarter Fiscal 2023 Vyleesi® Product Revenue Results

July 11, 2023

Palatin Presents Preclinical Diabetic Nephropathy Data at the International Podocyte Conference

May 30, 2023

Palatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

May 16, 2023

Palatin to Report Third Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on May 16, 2023

May 11, 2023

Newer

Page 2 of 29

Older